Pages
Products

AAV1-CMV-FLPo

For research use only. Not intended for any clinical use.

Cat. No. :   AAV00135Z

Serotype :   AAV Serotype 1 Storage :   -80 ℃

Titer: Size:

Inquire for Price

Virus Particles Information

Quality Control

Cat. No. AAV00135Z
Description AAV serotype 1 particles contain FLPo recombinase under the control of CMV promoter.
Serotype AAV Serotype 1
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 100 μL, 500 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Summary Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Q & A

Customer Reviews

Adeno-associated virus (AAV), originally discovered as a contaminant in simian adenovirus preparations, has become a popular candidate for therapeutic gene transfer vector systems. AAV is a member of the Parvoviridae family with a 4.7 kb single-stranded genome housed in a non-enveloped T=1 icosahedral capsid. AAV has been isolated from a variety of animal samples, including humans, non-human primates, goats, cattle, and avian samples. However, a defining characteristic of AAV is its apparent dependence on helper virus co-infection (such as adenovirus or herpes virus) for efficient replication.

Due to many features inherent to its viral biology, AAV has also been widely used as a gene transfer vector. AAV is disease-independent, has a broad and promiscuous tropism, is minimally immunogenic, and allows for efficient and long-lasting gene transfer. By eliminating all viral open reading frames in the viral genome, replication-defective AAV virus-like particles (also known as recombinant AAV or rAAV) containing heterologous genetic information can be assembled and packaged to obtain high vector yields for gene transfer applications. When loaded with therapeutic transgenes, the clinical safety and efficacy of AAV has been demonstrated for the treatment of inherited blindness and hemophilia B. In the preclinical phase, many approaches using AAV have been explored, including treatment paradigms for monogenic inherited diseases, complex acquired diseases, and infectious diseases such as influenza and HIV.

Site-specific recombinases (SSRs) are critical for achieving precise spatiotemporal control of engineered alleles. However, multiple recombination in complex alleles can be laborious. Here, researchers present an efficient method for in vitro allelic conversion using Cre, FLP (flippase), Dre, and Vika recombinases using adeno-associated virus (AAV) as a delivery vector. AAV enables efficient allelic switching in reporter mouse lines with minimal toxicity. Furthermore, AAV facilitates sequential allelic switching, which is critical for complete switching of alleles with multiple recombination sites, often found in conditional knockout mouse models. While simple allelic conversions showed 100% efficiency rates, complex multiple conversions consistently achieved 80% conversion rates. Overall, this strategy significantly reduces the need for animals and significantly speeds up the process of allelic conversion, representing a major improvement in genome engineering technology.

Utilizing the identified optimal titers for AAV recombinases, researchers achieved significant transformation efficiencies of 100% using AAV EF1a-Flpo, AAV CMV-Cre, -Dre, and -Vika vectors. Notably, in the case of the AAV CMV-Flpo vector, researchers observed a transformation rate of 92.6% of born animals, of which 2 (7.4%) showed chimerism and 2 (7.4%) showed no recombination. To increase Flpo conversion efficiency, researchers used an EF1a-Flpo vector with a titer of 1E + 11 GC/mL to convert MuX embryos. Using the EFlpo vector, 100% conversion was achieved. These findings indicate that AAV-Flpo treatment does not interfere with embryo viability at later stages of development and that treated zygotes have the potential to produce fully transformed animals. One fully-converted male animal from each AAV treatment group was then selected and analyzed for EGFP signal in the liver, lungs, skin (ear), heart, intestine, and testicles. All converted animals were EGFP positive in the organs analyzed (Figure 1).

Imaging of EGFP signal in fully-converted animals by AAV-SSR vectors (Cre, Dre, Vika and CMV-Flpo, EF1a-Flpo).Figure 1. Imaging of EGFP signal in fully-converted animals by AAV-SSR vectors (Cre, Dre, Vika and CMV-Flpo, EF1a-Flpo). (Nickl P, et al., 2024)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Consistent Results

The consistency of results was particularly impressive, making it a staple in our research protocols.

Canada

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction